Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technology to create new and potentially best-in-class therapies.
Ascendis Pharma currently has a pipeline of three wholly-owned, independent rare disease endocrinology product candidates in clinical development. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology and continues to expand into additional therapeutic areas for both internal and external development.
TransCon CNP is designed to provide long-term CNP exposure with the goal of optimizing efficacy with a well-tolerated and convenient once weekly dose. A phase 1 trial of TransCon CNP in healthy adult subjects is ongoing with top-line data anticipated in the fourth quarter of 2018.
Ascendis is headquartered in Copenhagen, Denmark, with offices in Heidelberg, Germany and Palo Alto, California.
***
Kennett Sprogøe, is the Senior Vice President of Ascendis Pharma
